15:05 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Galapagos reports CF data, provides update on AbbVie partnership

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc. (NYSE:ABBV) has scrapped plans for...
00:47 , Jun 29, 2018 |  BC Extra  |  Clinical News

Galapagos falls on CF data, AbbVie partnership update

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) shares slid Friday after the company said GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc....
19:15 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Galapagos reports Phase II data for GLPG2222 in CF

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from the Phase II FLAMINGO trial in 59 cystic fibrosis patients who were homozygous for the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) mutation showing that four...
23:27 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The double-blind, international trial enrolled 37 CF patients...
00:00 , Nov 21, 2017 |  BC Extra  |  Clinical News

Galapagos reports Phase II CF data for GLPG2222 combo

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said cystic fibrosis candidate GLPG2222 plus Kalydeco ivacaftor significantly reduced sweat chloride levels vs. placebo plus Kalydeco in the Phase II ALBATROSS trial. The trial enrolled 37 CF patients on long-term...
00:55 , Mar 29, 2017 |  BC Week In Review  |  Clinical News

GLPG3067: Ph I started

Galapagos began a double-blind, placebo-controlled, dose-escalation, Belgian Phase I trial to evaluate GLPG3067 in ≥48 healthy volunteers. Part I of the study will evaluate single ascending doses of GLPG3067 and part II will evaluate ascending...
17:37 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

GLPG2222: Ph IIa ALBATROSS started

Galapagos began the double-blind, placebo-controlled Phase IIa ALBATROSS trial to evaluate 2 dose levels of once-daily oral GLPG2222 plus Kalydeco ivacaftor for 29 days in up to 35 patients with a delta F508 CFTR mutation...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

GLPG2222: Phase I data

A double-blind, placebo-controlled, Belgian Phase I trial in about 40 healthy volunteers showed that single ascending doses of up to 800 mg oral GLPG2222 and once-daily ascending doses of up to 600 mg oral GLPG2222...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Galapagos, AbbVie deal

Galapagos received a $10 million milestone payment under a 2013 deal with AbbVie to develop and commercialize oral potentiators and correctors of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The payment...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

GLPG2222: Phase I started

Galapagos began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate single and multiple ascending doses of oral GLPG2222 in about 40 healthy volunteers. The trial start triggered a $10 million milestone payment to Galapagos...